Key Takeaways BMY's Reblozyl posted Q1 sales of $478M, up 35% year over year, highlighting strong growth momentum. Reblozyl missed the primary endpoint in a phase III study for myelofibrosis-associated anemia treatment. BMY aims to consult FDA and EMA despite mixed phase III study results.Bristol Myers’ ((BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati a ...